{"id":2416,"date":"2026-03-24T10:00:00","date_gmt":"2026-03-24T10:00:00","guid":{"rendered":"https:\/\/livingdiabetes.com\/?p=2416"},"modified":"2026-03-11T01:57:07","modified_gmt":"2026-03-11T01:57:07","slug":"aspirin-and-diabetes-what-the-current-guidelines-actually-say","status":"publish","type":"post","link":"https:\/\/livingdiabetes.com\/ur\/aspirin-and-diabetes-what-the-current-guidelines-actually-say\/","title":{"rendered":"Aspirin and Diabetes: What the Current Guidelines Actually Say"},"content":{"rendered":"
\n

For decades, low-dose aspirin was routinely recommended for people with diabetes as a cardiovascular preventive measure. Recent large-scale trials have fundamentally changed this approach. The current evidence suggests that aspirin’s benefits in diabetes are far more limited than previously believed \u2014 and its risks more significant. Here is what the latest guidelines actually say.<\/p>\n<\/div>\n

How Aspirin Works<\/h2>\n

Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and COX-2 enzymes, reducing the production of thromboxane A2 in platelets. This reduces platelet aggregation and clot formation \u2014 the mechanism by which aspirin prevents heart attacks and strokes in people with established cardiovascular disease.<\/p>\n

The Evidence: ASCEND and ARRIVE Trials<\/h2>\n

Two landmark trials published in 2018 fundamentally altered the aspirin landscape in diabetes. The ASCEND trial enrolled 15,480 people with diabetes without established cardiovascular disease and randomised them to aspirin 100mg daily or placebo. Aspirin reduced serious vascular events by 12% \u2014 but this benefit was almost exactly offset by a 29% increase in major bleeding events (gastrointestinal and intracranial haemorrhage). The net clinical benefit was essentially neutral.<\/p>\n

The ARRIVE trial similarly found no benefit of aspirin in moderate-risk patients without established cardiovascular disease, with bleeding complications outweighing any cardiovascular protection.<\/p>\n

\u26a0\ufe0f Current ADA 2025 Recommendations on Aspirin<\/strong><\/p>\n\n\n\n\n\n
Patient Group<\/th>\nAspirin Recommendation<\/th>\n<\/tr>\n
Established CVD (secondary prevention)<\/td>\nRecommended<\/strong> \u2014 75\u2013100mg daily<\/td>\n<\/tr>\n
High CV risk without established CVD<\/td>\nConsider<\/strong> \u2014 if bleeding risk is low; shared decision-making<\/td>\n<\/tr>\n
Low-to-moderate CV risk (primary prevention)<\/td>\nNot recommended<\/strong> \u2014 bleeding risk outweighs benefit<\/td>\n<\/tr>\n<\/table>\n<\/div>\n

Who Should Take Aspirin?<\/h2>\n

Aspirin remains clearly indicated for secondary prevention<\/strong> \u2014 that is, in people who have already had a heart attack, stroke, or have undergone coronary revascularisation. In this group, the benefits are well-established and the risk-benefit balance is clearly favourable.<\/p>\n

For primary prevention<\/strong> (people with diabetes who have not yet had a cardiovascular event), aspirin is no longer routinely recommended. The decision should be individualised based on cardiovascular risk, bleeding risk, age, and patient preference \u2014 discussed in a shared decision-making conversation with your doctor.<\/p>\n

\ud83d\udca1 Key Takeaway<\/strong><\/p>\n

If you have established cardiovascular disease, continue aspirin as directed. If you are taking aspirin for primary prevention of cardiovascular disease and have not had a heart attack or stroke, discuss with your doctor whether it is still appropriate \u2014 the evidence no longer supports routine use in this group. Never stop aspirin without medical advice if you have established CVD.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

For decades, low-dose aspirin was routinely recommended for people with diabetes as a cardiovascular preventive measure. Recent large-scale trials have fundamentally changed this approach. The current evidence suggests that aspirin’s benefits in diabetes are far more limited than previously believed \u2014 and its risks more significant. Here is what the latest guidelines actually say. How…<\/p>","protected":false},"author":2,"featured_media":2460,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_wpsp_custom_templates":["a:7:{s:8:\"facebook\";a:3:{s:8:\"template\";s:0:\"\";s:8:\"profiles\";a:0:{}s:9:\"is_global\";b:0;}s:7:\"twitter\";a:3:{s:8:\"template\";s:0:\"\";s:8:\"profiles\";a:0:{}s:9:\"is_global\";b:0;}s:8:\"linkedin\";a:3:{s:8:\"template\";s:0:\"\";s:8:\"profiles\";a:0:{}s:9:\"is_global\";b:0;}s:9:\"pinterest\";a:3:{s:8:\"template\";s:0:\"\";s:8:\"profiles\";a:0:{}s:9:\"is_global\";b:0;}s:9:\"instagram\";a:3:{s:8:\"template\";s:0:\"\";s:8:\"profiles\";a:0:{}s:9:\"is_global\";b:0;}s:6:\"medium\";a:3:{s:8:\"template\";s:0:\"\";s:8:\"profiles\";a:0:{}s:9:\"is_global\";b:0;}s:7:\"threads\";a:3:{s:8:\"template\";s:0:\"\";s:8:\"profiles\";a:0:{}s:9:\"is_global\";b:0;}}"],"_thumbnail_id":["2460"],"tpg-post-view-count":["43"]},"categories":[192,49,1],"tags":[277,276,279,278,51,280],"class_list":["post-2416","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-diabetes-education","category-endocrinology","category-type-2-diabetes","tag-antiplatelet-therapy","tag-aspirin","tag-bleeding-risk","tag-cardiovascular-prevention","tag-diabetes","tag-guidelines"],"rttpg_featured_image_url":{"full":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin.jpg",1200,675,false],"landscape":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin.jpg",1200,675,false],"portraits":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin.jpg",1200,675,false],"thumbnail":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin-150x150.jpg",150,150,true],"medium":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin-300x169.jpg",300,169,true],"large":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin-1024x576.jpg",640,360,true],"1536x1536":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin.jpg",1200,675,false],"2048x2048":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin.jpg",1200,675,false],"trp-custom-language-flag":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin-18x10.jpg",18,10,true],"post-thumbnail":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin-300x169.jpg",300,169,true],"minimalistblogger-grid":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin-350x230.jpg",350,230,true],"minimalistblogger-slider":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin-850x478.jpg",850,478,true],"minimalistblogger-small":["https:\/\/livingdiabetes.com\/wp-content\/uploads\/2026\/03\/feb17_aspirin-300x180.jpg",300,180,true]},"rttpg_author":{"display_name":"FWA","author_link":"https:\/\/livingdiabetes.com\/ur\/author\/manus\/"},"rttpg_comment":0,"rttpg_category":"Diabetes Education<\/a> Endocrinology<\/a> Type 2 diabetes<\/a>","rttpg_excerpt":"For decades, low-dose aspirin was routinely recommended for people with diabetes as a cardiovascular preventive measure. Recent large-scale trials have fundamentally changed this approach. The current evidence suggests that aspirin’s benefits in diabetes are far more limited than previously believed \u2014 and its risks more significant. Here is what the latest guidelines actually say. How...","_links":{"self":[{"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/posts\/2416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/comments?post=2416"}],"version-history":[{"count":1,"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/posts\/2416\/revisions"}],"predecessor-version":[{"id":2461,"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/posts\/2416\/revisions\/2461"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/media\/2460"}],"wp:attachment":[{"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/media?parent=2416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/categories?post=2416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/livingdiabetes.com\/ur\/wp-json\/wp\/v2\/tags?post=2416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}